‘Pent-up demand’ for FDA-approved cannabis drug boosts UK maker

Just Released! Get realistic market forecasts, state-by-state insights and benchmarks with the new 2024 MJBiz Factbook member program, now with quarterly updates. Make informed decisions.

Strong patient interest in the only federally approved CBD product in the United States helped drugmaker GW Pharmaceuticals record $72 million in revenue last quarter.

Epidiolex, which is made by London’s GW Pharma (Nasdaq: GWPH), is a seizure control drug approved by the U.S. Food and Drug Administration.

It has seen brisk sales and new patient enrollments since the drug’s launch last November.

The company said Epidiolex sales were $68.4 million for the quarter that ended in June.

It also reported Epidiolex has been used by more than 12,000 patients coming from about 2,500 physicians since its launch.

Company executives say Epidiolex is benefiting from “pent-up demand” for a regulated CBD treatment.

For more about where the company thinks pharmaceutical CBD is headed, click here.